» Articles » PMID: 28716467

Clinically Relevant Potential Drug-drug Interactions Among Outpatients: A Nationwide Database Study

Overview
Publisher Elsevier
Specialty Pharmacy
Date 2017 Jul 19
PMID 28716467
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adverse drug events due to drug-drug interactions (DDIs) represent a considerable public health burden, also in Slovenia. A better understanding of the most frequently occurring potential DDIs may enable safer pharmacotherapy and minimize drug-related problems.

Objectives: The aim of this study was to evaluate the prevalence and predictors of potential DDIs among outpatients in Slovenia.

Methods: An analysis of potential DDIs was performed using health claims data on prescription drugs from a nationwide database. The Lexi-Interact Module was used as the reference source of interactions. The influence of patient-specific predictors on the risk of potential clinically relevant DDIs was evaluated using logistic regression model.

Results: The study population included 1,179,803 outpatients who received 15,811,979 prescriptions. The total number of potential DDI cases identified was 3,974,994, of which 15.6% were potentially clinically relevant. Altogether, 9.3% (N = 191,213) of the total population in Slovenia is exposed to clinically relevant potential DDIs, and the proportion is higher among women and the elderly. After adjustment for cofactors, higher number of medications and older age are associated with higher odds of clinically relevant potential DDIs. The burden of DDIs is highest with drug combinations that increase risk of bleeding, enhance CNS depression or anticholinergic effects or cause cardiovascular complications.

Conclusion: The current study revealed that 1 in 10 individuals in the total Slovenian population is exposed to clinically relevant potential DDIs yearly. Taking into account the literature based conservative estimate that approximately 1% of potential DDIs result in negative health outcomes, roughly 1800 individuals in Slovenia experience an adverse health outcome each year as a result of clinically relevant potential interactions alone.

Citing Articles

Exploring potential drug-drug interactions in discharge prescriptions: ChatGPT's effectiveness in assessing those interactions.

Thapa R, Karki S, Shrestha S Explor Res Clin Soc Pharm. 2025; 17:100564.

PMID: 39896176 PMC: 11786904. DOI: 10.1016/j.rcsop.2025.100564.


The European Drug-Drug Interaction (EuroDDI) Study Protocol: A Cross-Country Comparison of Drug-Drug Interaction Prevalence in the Older Community-Dwelling Population.

Hughes J, Menditto E, Mucherino S, Orlando V, Moreno-Juste A, Gimeno-Miguel A Pharmacoepidemiol Drug Saf. 2025; 34(1):e70092.

PMID: 39777812 PMC: 11706702. DOI: 10.1002/pds.70092.


Informational continuity of medication management in transitions of care: Qualitative interviews with stakeholders from the HYPERION-TransCare study.

Dinh T, Hanf M, Klein A, Brueckle M, Rietschel L, Petermann J PLoS One. 2024; 19(4):e0300047.

PMID: 38573912 PMC: 10996284. DOI: 10.1371/journal.pone.0300047.


The Prevalence and Severity of Potential Drug-Drug Interactions in Internal Medicine Ward at Soba Teaching Hospital.

Hamadouk R, Alshareif E, Hamad H, Yousef B Drug Healthc Patient Saf. 2023; 15:149-157.

PMID: 37933264 PMC: 10625782. DOI: 10.2147/DHPS.S436458.


Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia.

Lalatovic N, Pantovic S, Nedovic-Vukovic M, Kostic M Iran J Public Health. 2023; 52(7):1466-1475.

PMID: 37593497 PMC: 10430412. DOI: 10.18502/ijph.v52i7.13248.